Companies › Xfibra
1 active drug program in 1 registered trial: 1 Phase 1; Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| XFB19 C/EBPβ Thr266 phosphorylation inhibitor targeting NLRP3 inflammasome activation | CEBPB | Phase 1 | Focus of the Study: Safety of XFB19 | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05361733 | XFB19 | Phase 1 | Focus of the Study: Safety of XFB19 | Other | Dec 2026 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.